This story originally ran on May 25.
The National Cancer Institute's Clinical Proteomic Technologies for Cancer Initiative this week issued a request for targets for monoclonal antibody production and characterization as part of its Antibody Characterization Program.
The call is part of a pilot effort exploring CPTC's "technical and practical ability to receive requests from the extramural research community for the production and characterization of monoclonal antibodies to cancer-associated targets," CPTC program manager Tara Hiltke told ProteoMonitor.
The organization expects it will generate antibodies from 40 to 50 targets selected from the submitted requests, she said, and anticipates additional solicitations "in the near future" provided this initial round is successful.
The Antibody Characterization program generates monoclonal antibodies to protein associated with human cancer for use in the CPTC initiative. Three antibodies are generated for each protein target and characterized using assays including isotype, SDS-PAGE, Western blot, ELISA, immunohistochemistry, immuno mass spectroscopy, and surface plasmon resonance.
Antibodies and hybridoma cells are made available to researchers through the Developmental Studies Hybridoma Bank at the University of Iowa and other third-party resources.
The submission period for protein target requests runs until July 1 and target selection notification will be on or before Aug. 1. All materials – i.e. proteins or peptides – to be used for antibody development must be ready and available at the time of the request submission.